Classification of patients with relapsed/refractory large B-cell lymphoma who do not develop early CRS/NE toxicity using ZUMA clinical trial data

We illustrated that routine clinicopathologic variables can be used to identify patients at low risk of developing early post-treatment CRS and/or NE. Such knowledge can be used to help treating centers prospectively manage patient care, including consideration of outpatient treatment.